NORD Stock Recent News

Beverly Hills, California., July 03, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves in the U.S. market, today announced it will host a webinar for existing and prospective investors on Wednesday, July 10, 2024, at 9:00 AM Pacific time / 12:00 PM Eastern time / 6:00 PM CET.

Beverly Hills, California., June 21, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a Consultancy Agreement with BIO-CONVERT in Denmark.

Beverly Hills, California., June 11, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, and its 95% owned subsidiary, Orocidin A/S (“Orocidin”), announced today new insights into the treatment of periodontitis.

Beverly Hills, California, June 04, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, announced today the appointment of Peter Severin as Chairman of the Board of Directors. Peter Severin replaces Christian Hill-Madsen as Chairman, who resigned to focus on developing the next generation of periodontities therapies for Orocidin A/S, a company owned 95% by Nordicus, where Christian currently serves as Chairman of its Board.

Beverly Hills, California., May 23, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced on the 15th of May, 2024 the acquisition of a 95% stake in Orocidin A/S (“Orocidin”) and announced today that it has engaged investor awareness specialists, FORCE Family Office (“FORCE”). Representing the world's largest community of Family Offices, Foundations, and Endowments, FORCE will be sharing Nordicus' and Orocidin's story with this community in upcoming webinars along with other events and activities.

Beverly Hills, California., May 15, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire a 95% stake from eleven of Orocidin's shareholders for $38,000,000. Nordicus will be issuing 38 million restricted common shares in an all-stock transaction to the selling shareholders.